Reproductive Endocrinology Ovarian Hormones

Can Inhibin B Reflect Ovarian Reserve of Healthy Reproductive Age Women Effectively?

Wen J, Huang K, Du X, Zhang H, Ding T, Zhang C, Ma W, Zhong Y, Qu W, Liu Y, Li Z, Deng S, Luo A, Jin Y, Zhang J, Wang S

Frontiers in Endocrinology, 2021
DOI 10.3389/fendo.2021.626534 PMID 33935966 PMC PMC8081350

RRM Academy Synopsis

Inhibin B tracks AMH and follicle count in healthy Chinese women

A prospective multicenter study of healthy Chinese women found that inhibin B fell sharply after age 40 and tracked AMH and antral follicle count. Researchers analyzed 1553 of 2524 recruited women, building the age pattern in 948 and checking it in 605. In these women, inhibin B flagged a low antral follicle count (below 5-7) slightly better than FSH.

Key Findings

  • The study recruited 2524 healthy Chinese women. After exclusions, 1553 were analyzed: 948 to establish the reference range and 605 to validate it.
  • Inhibin B stayed at similar levels from ages 20 to 35 and decreased significantly in women over 40.
  • Higher inhibin B went with higher AMH (R = 0.57, P < 0.001) and higher AFC (R = 0.34, P < 0.001), and with lower FSH (R = -0.41, P < 0.001).
  • Inhibin B had a weak positive link with testosterone, R = 0.10 (P = 0.002), and a negative link with LH (R = -0.20, P < 0.001).
  • For picking out AFC < 5-7, inhibin B had AUC = 0.74 and 0.78 in the establishment and validation groups. FSH had AUC = 0.71 and 0.72.

Interpretation

The study is a prospective, open-label database of healthy Chinese women recruited through advertisements at several centers. Blood was drawn in the follicular phase, or on day 2 to 5 of the cycle. The AUC (area under the curve) runs from 0.5 for chance to 1.0 for a perfect marker, and it summarizes how well a marker flags a low follicle count. The authors note that the study had no fertility or ART outcome data, so follicle count served as the target.

RRM Context

AMH, antral follicle count and FSH describe the size of the remaining follicle pool, and this dataset places inhibin B in that group. Restorative reproductive medicine treats a reserve marker as one input. The evaluation also looks for the cause of any fertility difficulty, using cycle charting and the couple's full history.

Abstract

Objective

The reference range and potential value of inhibin B are still unclear and controversial. This study aimed to define the variation trend of inhibin B in healthy women with age and explore its value in the reflection of ovarian reserve.

Methods

A total of 2524 healthy reproductive age women from eight medical institutes nationwide were recruited. The variation tendency of inhibin B with age was primarily established in the first group of 948 women and validated in another 605. We evaluated the relationship between inhibin B and classic ovarian reserve and function markers. The potency of inhibin B in predicting AFC <5-7 was also estimated and compared with FSH.

Results

The nomogram showed that serum levels of inhibin B rapidly decreased after the age of 40. Inhibin B was positively correlated with AMH (R = 0.57, P < 0.001), AFC (R = 0.34, P < 0.001) and testosterone (R = 0.10, P = 0.002), and negatively correlated with FSH (R = -0.41, P < 0.001) and LH (R = -0.20, P < 0.001) and FSH/LH (R=-0.18, P < 0.001), while no correlation was found with PRL. Unexpectedly, Inhibin B (AUC = 0.74, P < 0.001 for the establishment population; AUC = 0.78, P < 0.001 for the validation population) had a slightly higher value than FSH (AUC = 0.71, P < 0.001 for the establishment population; AUC = 0.72, P < 0.001 for the validation population) in diagnosing AFC <5-7.

Conclusions

For healthy reproductive age women, the decline of inhibin B can reflect decreased ovarian reserve effectively, having a good consistency with AMH and AFC. More importantly, inhibin B had an advantage in predicting AFC <5-7 compared with FSH, which suggested the potential of inhibin B in predicting ovarian response. These results will be helpful to the clinical application of inhibin B in the evaluation of female ovarian reserve and the assessment of their reproductive capacity.

Trial Registration

http://clinicaltrials.gov; NCT02294500.

Topics

By this author

Related research

Reproductive Endocrinology › Ovarian Hormones › Estrogen · Diagnostics › Hormone Testing › Serum Panels · Longevity and Reproductive Aging › Reproductive Aging › Ovarian Aging
Jingyi Wen, Kecheng Huang, Xiaofang Du, Hanwang Zhang, Ting Ding, Cuilian Zhang, Wenmin Ma, Ying Zhong, Wenyu Qu, Yi Liu, Zhiying Li, Song Deng, Aiyue Luo, Yan Jin, Jinjin Zhang, Shixuan Wang
J Wen, K Huang, X Du, H Zhang, T Ding, C Zhang, W Ma, Y Zhong, W Qu, Y Liu, Z Li, S Deng, A Luo, Y Jin, J Zhang, S Wang
PMID 33935966 33935966 DOI 10.3389/fendo.2021.626534 10.3389/fendo.2021.626534 Wen et al. 2021, Wen 2021